Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

China flag China · Delayed Price · Currency is CNY
15.80
+0.16 (1.02%)
Sep 30, 2025, 3:00 PM CST
1.02%
Market Cap23.60B
Revenue (ttm)8.41B
Net Income (ttm)1.07B
Shares Out1.49B
EPS (ttm)0.72
PE Ratio22.02
Forward PE13.39
Dividend0.53 (3.35%)
Ex-Dividend Daten/a
Volume15,031,522
Average Volume19,047,237
Open15.64
Previous Close15.64
Day's Range15.59 - 15.82
52-Week Range13.51 - 17.77
Beta0.34
RSI41.74
Earnings DateOct 24, 2025

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China. [Read more]

Sector Healthcare
Founded 1994
Employees 10,958
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600535
Full Company Profile

Financial Performance

In 2024, SHA:600535's revenue was 8.50 billion, a decrease of -2.03% compared to the previous year's 8.67 billion. Earnings were 955.59 million, a decrease of -10.78%.

Financial Statements

News

There is no news available yet.